---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031624"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:52:24.619689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR

## Summary
- Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
- Net loss $51M ($0.46/ADS); operating loss $69.4M; cash $761.3M at March 31.
- Zoci (DLL3 ADC) delivered 62.5% confirmed intracranial ORR in SCLC brain mets at AACR; 38.2% ORR in epNECs.
- Clinical collaborations with Amgen and Boehringer Ingelheim to evaluate zoci combinations in SCLC and NECs.
- Appointed Yizhe Wang, Ph.D., as Operating Partner; KarXT launch preparations underway; TIVDAK under regulatory review.

## SEC filing metadata
- accession: 0001628280-26-031624
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/0001628280-26-031624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031624
- JSON: https://secwatch.observer/filing/0001628280-26-031624.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031624.txt

## Source-grounded claims
- claim_id: d0159a19ea25e72765570fcd0aa027e59bc8522d
  claim: Zai Lab Ltd reported the first quarter of 2026 results: revenue $99.6 million, net income Net loss was $51.0 million, EPS loss per ADS of $0.46.
  evidence_excerpt: forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates – Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/0001628280-26-031624-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.